Compare Merck & Co., Inc. (MRK) vs MasTec Inc (MTZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs MasTec Inc — how do they compare? Merck & Co., Inc. trades at $145.6 (market cap $351.28B), while MasTec Inc trades at $212.65 (market cap $17.40B). The key difference: Merck & Co., Inc. is far larger — about 20.2× MasTec Inc's market cap, and Merck & Co., Inc. pays a 2.39% dividend while MasTec Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and MasTec Inc for 23 Days on average.
| MRK | MTZ | |
|---|---|---|
Market Cap | $351.28B | $17.40B |
Volume | 7,969,665 | 1,415,821 |
Sector | Health | Industrials |
52-Week High | $156.43 | $437.51 |
52-Week Low | $82.49 | $190.08 |
Typical Hold Time | 98 Days | 23 Days |
Enterprise Value | $398.04B | $20.32B |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.40, down 0.28% on the day, with a bearish technical signal and key support at $140. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.14. Revenue grew to $65.01B in 2025, and net income reached $18.25B, though the P/E ratio is elevated at 113.9. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
The outlook for MRK is mixed, with solid fundamentals and analyst optimism countered by high valuation and bearish technicals. The consensus price target of $158.78 suggests upside potential, but investors face risks from competitive pressures and integration challenges from recent M&A activity. Earnings growth and pipeline developments remain key catalysts.
MasTec (MTZ) trades at $216.66, down 3.0% on the day, with technical indicators showing bearish momentum as the stock trades below key moving averages. The company reported strong Q1 2026 earnings beat but missed Q2 expectations, while maintaining robust revenue growth projections for 2026. Analyst sentiment remains overwhelmingly positive with 89% buy ratings and a consensus price target of $408.58, representing significant upside potential from current levels.
MTZ presents a compelling growth story with record $21.4B backlog and exposure to infrastructure investment cycles, though premium valuation metrics and recent cash flow weakness warrant caution. The stock's current discount to analyst targets offers opportunity, but execution risks in communications segment and competitive pressures require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About MasTec Inc
MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →
